Abstract Background Serology testing of antibodies against SARS-CoV-2 viruses serves many purposes: disease diagnosis, on-going and surveillance, epidemiologic and vaccine studies, etc. There was a critical need to provide standardized quality control materials for development and harmonization across different test methods and IVD platforms. The MAS™ SARS-CoV-2 IgG Controls are human plasma-based materials containing IgG antibodies against SARS-CoV-2. The control offers commutability by mimicking patient samples and is intended to be used for monitoring serological assays, providing confidence in routine test results, test methods troubleshooting and system errors identification. We report here the compatibility assessment of MAS™ SARS-CoV-2 Controls testing on different assays and platforms. Methods The platforms and assays compatibility was assessed for the MAS™ SARS-CoV-2 IgG Positive and Negative Controls across all 11 assays and platforms listed as below. These serology assays target either total antibodies (IgA, IgM, IgG), IgM/IgG, or IgG against either the SARS-CoV-2 nucleocapsid (N), RBD or spike (S) proteins. Replicated samples were tested on each instrument for statistical confidence. Results All results demonstrated conclusively the comparable performance of MAS™ SARS-CoV-2 IgG controls across different clinical diagnostic assays and platforms manufactured by Abbott, Roche, Ortho, DiaSorin, Beckman Coulter and bioMérieux. The positive control showed 100% expected reactive results (IgG Positive) and Negative control at 82% non-reactive results, respectively. Furthermore, both controls were compatible towards assays detecting IgG antibodies targeting specific regions (N, S or RBD). Conclusion SARS-CoV-2 serology testing remains unstandardized with numerous assays and platforms receiving FDA EUA. While tested on multiple commonly used assays and platforms, MAS™ SARS-CoV-2 IgG Positive and Negative Controls were found to be platform agnostic. To conclude, MAS Controls will contribute to the harmonization of the SARS-CoV-2 Serology assay offerings, monitor the clinical laboratory analytical performance, streamline the workflow on test method development, validation and verification, and routine assessment.